Systemic cytokine levels in community-acquired pneumonia and their association with disease severity

European Respiratory Journal

Volumn 20, Issue 4, 2002, Pages 990-995

  Antunes, G ^a   Evans, S A ^a   Lordan, J L ^a   Frew, A J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Communiy acquired; Cytokines; Disease severity score; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CULTURE; CHLAMYDOPHILA PSITTACI; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; COXIELLA BURNETII; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HIGH RISK POPULATION; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; LEGIONELLA PNEUMOPHILA; MALE; MEDICAL ASSESSMENT; MEDICAL SOCIETY; MYCOPLASMA PNEUMONIAE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; SPUTUM CULTURE; SURVIVAL; THORAX RADIOGRAPHY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; APACHE; BIOLOGICAL MARKERS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; PNEUMONIA; PROBABILITY; PROGNOSIS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036798112     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00295102     Document Type: Article

References (30)

1. Hook EW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983; 249: 1055-1057.
2. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995; 107: 1342-1349.
3. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999; 54: 51-55.
4. Moussa K, Michie HJ, Cree IA, et al. Phagocyte function and cytokine production in community acquired pneumonia. Thorax 1994; 49: 107-111.
5. Gomez-Jimenez J, Martin MC, Sauri R, et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995; 171: 472-475.
6. Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125: 191-196.
7. Gardlund B, Sjolin J, Nilsson A, Roll M, Wickerts C-J, Wretlind B. Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity. J Infect Dis 1995; 172: 296-301.
8. De Bont ESJM, De Leij LHFM, Okken A, Baarsma R, Kimpen JLL. Increased plasma concentrations of interleukin-1 receptor antagonist in neonatal sepsis. Pediatr Res 1995; 37: 626-629.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-828.
10. Le Gall J-R, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-2963.
11. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community acquired pneumonia. J Gen Intern Med 1995; 10: 359-368.
12. Ewig S, Bauer T, Hasper E, Pizzulli L, Kubini R, Luderitz B. Prognostic analysis and predictive rule for outcome of hospital-treated community-acquired pneumonia. Eur Respir J 1995; 8: 392-397.
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
14. Research committee of the British Thoracic Society and the Public Health Laboratory Service. Community acquired pneumonia in adults in British hospitals in 1982-83: a survey of aetiology, mortality, prognostic and outcome. Q J Med 1987; 62: 195-220.
15. British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-350.
16. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
17. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000; 55: 219-223.
18. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994; 150: 710-716.
19. Menton C, Torres A, El-Ebiary M, Filella X, Xaubet A, De la Bellacasa JP. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 1999; 27: 1745-1753.
20. Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
21. Taniguchi T, Koido Y, Aiboshi J, Yamashita T, Suzaki S, Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-1264.
22. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-Reactive Protein. A clinical marker in community-acquired pneumonia. Chest 1995; 108: 1288-1291.
23. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993; 178: 2207-2211.
24. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63: 2109-2112.
25. Van Dissel JT, Van Langevelde P, Westendorp RGJ, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351: 950-953.
26. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998; 16: 457-499.
27. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 1996; 24: 1431-1440.
28. Opal SM, Fisher CJ, Pribble JP, et al. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25: 1115-1124.
29. Lu ZY, Brailly H, Wijdenes J, Rossi JF, Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 1995; 86: 3123-3131.
30. Tilg H, Trehu E, Atkins MB, Dinarello CA, Meir JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumour necrosis factor receptor p55. Blood 1994; 83: 113-118.